www.idosr.org Mpora, 2026

©IDOSR PUBLICATIONS ISSN: 2579-079X

International Digital Organization for Scientific Research IDOSR JST/26/1220000
IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 12(2):36-39, 2026.
https://doi.org/10.59298/IDOSR/JST/26/122.3639

SGLT2 Inhibitors: Cardiovascular and Renoprotective Outcomes in Type 2 Diabetes Mellitus

Mpora Kakwanzi Evelyn

Department of Pharmacognosy Kampala International University Uganda
Email: evelyne.mpora@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus (T2DM) is a leading cause of cardiovascular and renal complications worldwide, contributing significantly to morbidity and mortality. The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represented a novel therapeutic approach, offering not only glycemic control but also substantial cardiovascular and renal benefits. This review aimed to evaluate the cardiovascular and renoprotective outcomes of SGLT2 inhibitors in patients with T2DM, focusing on clinical trial findings, mechanisms of action, and safety considerations. A comprehensive review of key clinical studies, including the EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 trials, was conducted to assess the effects of SGLT2 inhibitors on cardiovascular and renal outcomes in T2DM patients. SGLT2 inhibitors significantly reduced the risk of heart failure, cardiovascular events, and chronic kidney disease progression in patients with T2DM. These drugs also protected against albuminuria and renal function decline, demonstrating promising long-term outcomes in high-risk populations. SGLT2 inhibitors have proven to be a transformative treatment for cardiovascular and renal protection in T2DM patients. Ongoing research is essential to further explore their broader applications and refine patient management strategies.

Keywords: SGLT2 inhibitors, Type 2 diabetes mellitus, Cardiovascular protection, Renal protection, Clinical trials.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic conditions globally, with an increasing incidence driven by obesity, aging populations, and sedentary lifestyles [1]. T2DM is a major risk factor for cardiovascular diseases, including heart failure, ischemic heart disease, and stroke [2, 3]. In addition to cardiovascular complications, individuals with T2DM are also at high risk for renal disease, with chronic kidney disease (CKD) being one of the most severe outcomes of prolonged hyperglycemia. As such, T2DM management has expanded beyond blood glucose control to address cardiovascular and renal protection, areas in which traditional antidiabetic therapies have limited efficacy.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a groundbreaking class of medications that provide more than just glycemic control [4, 5]. By inhibiting the SGLT2 protein in the kidneys, these drugs reduce glucose reabsorption, leading to increased glucose excretion through urine. This mechanism not only helps manage blood glucose levels but also induces a natriuretic effect, leading to reduced blood pressure and improved cardiovascular outcomes. Furthermore, SGLT2 inhibitors have been shown to slow the progression of chronic kidney disease (CKD), reduce albuminuria, and protect against heart failure [6]. This review aims to critically evaluate the cardiovascular and renoprotective outcomes of SGLT2 inhibitors in T2DM, focusing on clinical trial evidence from landmark studies such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58. We will also explore the pharmacological mechanisms behind these effects, the safety profile of SGLT2 inhibitors, and the implications for clinical practice. The purpose of this review is to provide a comprehensive understanding of how SGLT2 inhibitors have transformed the management of T2DM and their potential in improving long-term patient outcomes.

Pharmacology of SGLT2 Inhibitors

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral medications designed to block the SGLT2 protein in the proximal renal tubules. This protein is responsible for reabsorbing approximately 90% of filtered glucose from the urine back into the bloodstream [7, 8]. By inhibiting SGLT2, these medications prevent glucose

reabsorption, leading to increased urinary glucose excretion and a subsequent reduction in blood glucose levels. This mechanism offers an additional therapeutic option for patients with T2DM, particularly for those who are not achieving adequate glycemic control with other medications.

Beyond their glucose-lowering effects, SGLT2 inhibitors have unique properties that contribute to cardiovascular and renal benefits [9]. The natriuretic effect induced by these drugs leads to a mild diuresis, which can reduce blood pressure, a key contributor to both cardiovascular and renal disease. SGLT2 inhibition also enhances the availability of ketones as an alternative energy source, which has been postulated to improve myocardial and renal function, especially in patients with heart failure and CKD.

Importantly, SGLT2 inhibitors, such as empagliflozin, canagliflozin, and dapagliflozin, do not cause insulin secretion, reducing the risk of hypoglycemia [10, 11]. This makes them particularly useful in patients with concomitant cardiovascular disease or CKD, as they offer significant benefits without increasing the risk of adverse events commonly associated with other diabetes medications.

Clinical Trials and Cardiovascular Outcomes

The cardiovascular benefits of SGLT2 inhibitors were first highlighted in the EMPA-REG OUTCOME trial, which investigated the effects of empagliflozin in patients with T2DM and established cardiovascular disease (CVD) [12]. The trial demonstrated a significant reduction in the risk of cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients treated with empagliflozin compared to those receiving a placebo. These findings were groundbreaking, as they marked the first time a glucose-lowering drug had shown a reduction in cardiovascular mortality.

Subsequent clinical trials, including the CANVAS (Canagliflozin Cardiovascular Assessment Study) and DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events), further corroborated these results, showing that SGLT2 inhibitors consistently reduce the risk of hospitalization for heart failure, cardiovascular death, and other adverse cardiovascular events [13]. In the CANVAS trial, canagliflozin was shown to reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM, while DECLARE-TIMI 58 demonstrated that dapagliflozin significantly reduced the risk of hospitalization for heart failure and renal disease progression.

These trials highlight the ability of SGLT2 inhibitors to not only control blood glucose but also to provide significant protection against cardiovascular events, particularly in high-risk populations. The mechanism behind these benefits is thought to be related to the effects of SGLT2 inhibition on blood pressure, volume status, and myocardial metabolism, all of which contribute to improved cardiovascular outcomes in patients with T2DM.

Renoprotective Effects of SGLT2 Inhibitors

Chronic kidney disease (CKD) is a common and serious complication of T2DM, contributing to high morbidity and mortality in this population [14, 15]. SGLT2 inhibitors have emerged as a key therapeutic option for preventing the progression of CKD in T2DM patients. The renoprotective effects of SGLT2 inhibitors are well-documented in several major clinical trials, including EMPA-REG OUTCOME, CANVAS, and DAPA-HF (Dapagliflozin and Prevention of Heart Failure) [16].

In the EMPA-REG OUTCOME trial, empagliflozin was shown to significantly reduce albuminuria, a key marker of kidney damage, and slow the decline in glomerular filtration rate (GFR) [17, 18]. Similarly, the CANVAS trial demonstrated that canagliflozin reduced the risk of kidney disease progression, as measured by the composite outcome of doubling of serum creatinine, initiation of renal replacement therapy, or renal death.

The renoprotective effects of SGLT2 inhibitors are believed to stem from several mechanisms, including reduced hyperfiltration, improved tubulointerstitial health, and enhanced natriuresis [19]. By reducing the workload on the kidneys, these drugs help to prevent further damage to renal structures. Additionally, the reduction in albuminuria observed with SGLT2 inhibitors is a strong predictor of improved long-term renal outcomes, making these drugs an essential part of managing T2DM-related CKD.

Safety Profile and Adverse Effects

SGLT2 inhibitors have generally been well-tolerated in clinical trials, but they are not without potential risks. The most common adverse effects associated with these drugs include urinary tract infections (UTIs), genital infections, and dehydration [20]. These side effects are generally mild and can be managed with appropriate patient education and monitoring. The increased glucose excretion in urine can create a favorable environment for the growth of bacteria, leading to UTIs, particularly in women.

Another significant risk is diabetic ketoacidosis (DKA), a rare but serious complication that has been associated with SGLT2 inhibitors, particularly in patients with type 1 diabetes or those with very low insulin levels. Although the incidence of DKA is low, clinicians must be aware of this risk, especially during periods of acute illness or when insulin doses are reduced.

SGLT2 inhibitors can also cause a reduction in blood pressure due to their diuretic effect [21], which may be beneficial for patients with hypertension but can lead to volume depletion and dizziness, particularly in elderly patients. Regular monitoring of renal function, volume status, and electrolytes is essential to mitigate these risks.

Future Directions in SGLT2 Inhibitor Research

The success of SGLT2 inhibitors in improving cardiovascular and renal outcomes in T2DM has sparked interest in exploring their use in broader populations. Ongoing trials are investigating the effects of SGLT2 inhibitors in patients with heart failure and chronic kidney disease who do not have T2DM [22], as well as their potential benefits in preventing or treating conditions such as non-alcoholic fatty liver disease (NAFLD).

In addition, there is growing interest in understanding the long-term safety of SGLT2 inhibitors, particularly their effects on bone health, fractures, and cancer risk. Ongoing studies aim to clarify these concerns and further evaluate the long-term efficacy of these drugs in preventing diabetes-related complications.

CONCLUSION

SGLT2 inhibitors have revolutionized the management of T2DM, offering significant cardiovascular and renal benefits beyond glycemic control. Clinical trials, including EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58, have demonstrated the ability of these drugs to reduce cardiovascular death, hospitalization for heart failure, and the progression of chronic kidney disease. Their mechanisms of action, which involve glucose excretion, natriuresis, and improvement in myocardial and renal function, provide a multifaceted approach to managing patients with T2DM and concomitant cardiovascular or renal disease. Despite their proven benefits, SGLT2 inhibitors are associated with some adverse effects, including UTIs, genital infections, dehydration, and rare instances of diabetic ketoacidosis. These risks must be carefully managed, particularly in high-risk patients. SGLT2 inhibitors should be considered a cornerstone in the management of T2DM, particularly in patients with concurrent cardiovascular or renal disease. Continued research is essential to explore their broader applications in other patient populations and refine their long-term safety profile.

REFERENCES

1. Bellary, S., Kyrou, I., Brown, J.E., Bailey, C.J.: Type 2 diabetes mellitus in older adults: clinical considerations and management. Nat Rev Endocrinol. 17, 534–548 (2021). https://doi.org/10.1038/s41574-021-00512-2
2. Alum, E.U., Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
3. Low Wang, C.C., Hess, C.N., Hiatt, W.R., Goldfine, A.B.: Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation. 133, 2459–2502 (2016). https://doi.org/10.1161/CIRCULATIONAHA.116.022194
4. Youssef, M.E., Yahya, G., Popoviciu, M.S., Cavalu, S., Abd-Eldayem, M.A., Saber, S.: Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. International Journal of Molecular Sciences. 24, (2023). https://doi.org/10.3390/ijms24076039
5. Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: *In Vivo* and *in Silico* Evidence. Natural Product Communications. 19, 1934578X241299279 (2024). https://doi.org/10.1177/1934578X241299279
6. Mende, C.W.: Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv Ther. 39, 148–164 (2022). https://doi.org/10.1007/s12325-021-01994-2
7. Palmer, B.F., Clegg, D.J.: Kidney-Protective Effects of SGLT2 Inhibitors. Clinical Journal of the American Society of Nephrology. 18, 279 (2023). https://doi.org/10.2215/CJN.09380822
8. Gajewska, A., Wasiak, J., Sapeda, N., Młynarska, E., Rysz, J., Franczyk, B.: SGLT2 Inhibitors in Kidney Diseases—A Narrative Review. International Journal of Molecular Sciences. 25, (2024). https://doi.org/10.3390/ijms25094959
9. DeFronzo, R.A., Norton, L., Abdul-Ghani, M.: Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 13, 11–26 (2017). https://doi.org/10.1038/nrneph.2016.170
10. Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., Tentolouris, N.: SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health. 16, (2019). https://doi.org/10.3390/ijerph16162965
11. Johnston, R., Uthman, O., Cummins, E., Clar, C., Royle, P., Colquitt, J., Tan, B.K., Clegg, A., Shantikumar, S., Court, R., O'Hare, J.P., McGrane, D., Holt, T., Waugh, N.: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment. 21, 1–218 (2017). https://doi.org/10.3310/hta21020
12. Kyriakos, G., Quiles-Sanchez, L.V., Garmpi, A., Farmaki, P., Kyre, K., Savvanis, S., Antoniou, V.K., Memi, E.: SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Current Cardiology Reviews. 16, 258–265 (2020). https://doi.org/10.2174/1573403X15666190730094215
13. Vargas Delgado, A.P., Requena Ibañez, J.A., Santos-Gallego, C.G., Badimon, J.J.: Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment? Clínica e Investigación en Arteriosclerosis (English Edition). 33, 33–40 (2021). https://doi.org/10.1016/j.artere.2020.12.004

14. Thomas, M.C., Cooper, M.E., Zimmet, P.: Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 12, 73–81 (2016). https://doi.org/10.1038/nrneph.2015.173
15. Lv, J.-C., Zhang, L.-X.: Prevalence and Disease Burden of Chronic Kidney Disease. In: Liu, B.-C., Lan, H.-Y., and Lv, L.-L. (eds.) Renal Fibrosis: Mechanisms and Therapies. pp. 3–15. Springer, Singapore (2019)
16. Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A.D., Albanese, G., Salvo, J.D., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., Sasso, F.C.: An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences. 23, (2022). https://doi.org/10.3390/ijms23073651
17. Hadjadj, S., Cooper, M.E., Steubl, D., Petrini, M., Hantel, S., Mattheus, M., Wanner, C., Thomas, M.C.: Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial. Kidney Medicine. 6, 100783 (2024). https://doi.org/10.1016/j.xkme.2023.100783
18. Wanner, C., Heerspink, H.J.L., Zinman, B., Inzucchi, S.E., Koitka-Weber, A., Mattheus, M., Hantel, S., Woerle, H.-J., Broedl, U.C., von Eynatten, M., Groop, P.-H., Investigators, on behalf of the E.-R.O.: Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology. 29, 2755 (2018). https://doi.org/10.1681/ASN.2018010103
19. Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A.D., Albanese, G., Salvo, J.D., Epifani, R., Marfella, R., Docimo, G., Lettieri, M., Sardu, C., Sasso, F.C.: An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. International Journal of Molecular Sciences. 23, (2022). https://doi.org/10.3390/ijms23073651
20. Arakaki, R.F.: Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgraduate Medicine. 128, 409–417 (2016). https://doi.org/10.1080/00325481.2016.1167570
21. Maliha, G., Townsend, R.R.: SGLT2 inhibitors: their potential reduction in blood pressure. Journal of the American Society of Hypertension. 9, 48–53 (2015). https://doi.org/10.1016/j.jash.2014.11.001
22. Matthews, J., Herat, L., Schlaich, M.P., Matthews, V.: The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status. Int J Mol Sci. 24, 14243 (2023). https://doi.org/10.3390/ijms241814243

CITE AS: Mpora Kakwanzi Evelyn. (2026). SGLT2 Inhibitors: Cardiovascular and Renoprotective Outcomes in Type 2 Diabetes Mellitus. IDOSR JOURNAL OF SCIENCE AND TECHNOLOGY 12(2):36-39, 2026. https://doi.org/10.59298/IDOSR/JST/26/122.3639